R&D Commercialization Initiatives

BRIDGE Program: Mechanism of Action (MoA) Studies
External Collaboration Program
Program Objective
To facilitate technology transfer and advancement to the next development stage by establishing the mechanism of action (MoA) of early-stage drug candidates through practical mechanism studies and securing lead compounds.
Program Details
  • Program period: Apr-Dec, 2026
  • Scope of Support: (Small molecule & Antibody)
    • Structural and interaction analysis of drug–target protein complexes
    • Mechanism analysis reports and strategic consulting
    • Expression and purification of target proteins
Contact

R&D Enabling & Strategy Team: rnd_project@kddf.org